Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06780449
PHASE3

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

Sponsor: Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by chance and is not known by participants or the study doctor. In the extension phase participants will get either CagriSema or slowly reduce participants dose of CagriSema if participants had CagriSema in the main phase. Which treatment participants get is decided by chance and is not known by participants or the study doctor in both phases. If participants had "dummy medicine" in the main phase, participants will get CagriSema in the extension phase. Like all medicines, the study medicine may have side effects.

Official title: Long-term Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Placebo in Participants With Obesity

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

400

Start Date

2025-02-10

Completion Date

2028-10-31

Last Updated

2026-01-20

Healthy Volunteers

No

Conditions

Interventions

DRUG

Cagrilintide

Participants will receive cagrilintide subcutaneously.

DRUG

Semaglutide

Participants will receive semaglutide subcutaneously.

DRUG

Placebo cagrilintide

Participants will receive placebo matched to cagrilintide subcutaneously.

DRUG

Placebo semaglutide

Participants will receive placebo matched to semaglutide subcutaneously.

Locations (36)

Valley Clinical Trials

Covina, California, United States

Diablo Clinical Research, Inc.

Walnut Creek, California, United States

Yale University School Of Medicine

New Haven, Connecticut, United States

East West Medical Research Institute_Honolulu

Honolulu, Hawaii, United States

L-MARC Research Center

Louisville, Kentucky, United States

StudyMetrix Research LLC

City of Saint Peters, Missouri, United States

Spartanburg Medical Research

Spartanburg, South Carolina, United States

Holston Medical Group_Bristol

Bristol, Tennessee, United States

North Texas Endocrine Center

Dallas, Texas, United States

Washington Cntr Weight Mgmt

Arlington, Virginia, United States

Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie

Brussels, Belgium

UZA - UZ Antwerpen - Department of Endocrinology

Edegem, Belgium

UZ Leuven - Endocrinology

Leuven, Belgium

CHU Helora - Hôpital de Mons - Site Constantinople

Mons, Belgium

Dr. M.B. Jones Inc

Victoria, British Columbia, Canada

Nova Scotia Health Authority

Halifax, Nova Scotia, Canada

Premier Clinical Trial Research Network (PCTRN)

Hamilton, Ontario, Canada

Alpha Recherche Clinique - Lebourgneuf

Québec, Canada

Aarhus Universitetshospital, Steno Diabetes Center Aarhus

Aarhus, Denmark

Sydvestjysk Sygehus Esbjerg - Medicinsk Endokrinologisk Ambulatorium, Forskningsenheden

Esbjerg, Denmark

Gentofte Hospital - Center for Klinisk Metabolisk Forskning

Hellerup, Denmark

Hvidovre Hospital Endokrinologisk forsknings afsnit 159

Hvidovre, Denmark

Sjællands Universitetshospital, Køge - Medicinsk Afdeling

Køge, Denmark

ULS De Matosinhos E.P.E.- Hospital Pedro Hispano

Senhora Da Hora, Matosinhos, Matosinhos, Portugal

APDP - Associação Protectora dos Diabéticos de Portugal

Lisbon, Portugal

CUF Descobertas

Lisbon, Portugal

Hospital Cuf Descobertas S.A.

Lisbon, Portugal

Unidade Local de Saude de Sao Joao E.P.E

Porto, Portugal

Hospital Luz Arrabida, S.A.

Vila Nova de Gaia, Portugal

Southmead Hospital

Bristol, United Kingdom

Addenbrooke's Hospital_Cambridge

Cambridge, United Kingdom

University Hospital Coventry - WISDEM Centre

Coventry, United Kingdom

Aintree University Hospital

Liverpool, United Kingdom

Royal London Hospital - Blizard Institute

London, United Kingdom

Joint Clinical Research Facility - Swansea

Swansea, United Kingdom

Musgrove Park Hospital

Taunton, United Kingdom